How Many Mutant p53 Molecules Are Needed to Inactivate a Tetramer?

Molecular and Cellular Biology

Volumn 24, Issue 8, 2004, Pages 3536-3551

  Chan, Wan Mui ^a   Siu, Wai Yi ^a   Lau, Anita ^a   Poon, Randy Y C ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

MONOMER; PROTEIN P53; PROTEIN P63; PROTEIN P73; PROTEIN SUBUNIT; TETRAMER; TRANSCRIPTION FACTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CARCINOGENESIS; DNA BINDING; GENE INACTIVATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSACTIVATION;

CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, THEORETICAL; MUTATION; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN STRUCTURE, QUATERNARY; PROTEIN SUBUNITS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 1842609721     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.8.3536-3551.2004     Document Type: Article

References (54)

1. Aurelio, O. N., X. T. Kong, S. Gupta, and E. J. Stanbridge. 2000. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol. Cell. Biol. 20:770-778.
2. Ausubel, F., R. Brent, R. Kingston, D. Moore, J. Seidman, J. Smith, and K. Struhl. 1991. Current protocols in molecular biology. John Wiley & Sons, New York, N.Y.
3. Bodner, S. M., J. D. Minna, S. M. Jensen, D. D'Amico, D. Carbone, T. Mitsudomi, J. Fedorko, D. L. Buchhagen, M. M. Nau, A. F. Gazdar, et al. 1992. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 7:743-749.
4. Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a P53 mmor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346-355.
5. Chow, J. P. H., W. I. Siu, T. K. Fung, W. M. Chan, A. Lau, T. Arooz, C.-P. Ng, K. Yamashita, and R. Y. C. Poon. 2003. DNA damage during the spindle-assembly checkpoint degrades CDC25A, inhibits cyclin-CDC2 complexes, and reverses cells to interphase. Mol. Biol. Cell 14:3189-4002.
6. Davison, T. S., C. Vagner, M. Kaghad, A. Ayed, D. Caput, and C. H. Arrowsmith. 1999. p73 and p63 are homotetramers capable of weak heterotypic interactions with each other but not with p53. J. Biol. Chem. 274:18709-18714.
7. Denissenko, M. F., A. Pao, M. Tang, and G. P. Pfeifer. 1996. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 274:430-432.
8. de Vries, A., E. R. Flores, B. Miranda, H. M. Hsieh, C. T. van Oostrom, J. Sage, and T. Jacks. 2002. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl. Acad. Sci. USA 99:2948-2953.
9. Eliyahu, D., N. Goldfinger, O. Pinhasi-Kimhi, G. Shaulsky, Y. Skurnik, N. Arai, V. Rotter, and M. Oren. 1988. Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene 3:313-321.
10. Finlay, C. A., P. W. Hinds, and A. J. Levine. 1989. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083-1093.
11. Forrester, K., S. E. Lupold, V. L. Ott, C. H. Chay, V. Band, X. W. Wang, and C. C. Harris. 1995. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10:2103-2111.
12. Frebourg, T., M. Sadelain, Y. S. Ng, J. Kassel, and S. H. Friend. 1994. Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. Cancer Res. 54:878-881.
13. Fujita, M., T. Kiyono, Y. Hayashi, and M. Ishibashi. 1997. In vivo interaction of human MCM heterohexameric complexes with chromatin. Possible involvement of ATP. J. Biol. Chem. 272:10928-10935.
14. Fung, T. K., W. Y. Siu, C. H. Yam, A. Lau, and R. Y. C. Poon. 2002. Cyclin F is degraded during G2-M by mechanisms fundamentally different from other cyclins. J. Biol. Chem. 277:35140-35149.
15. Gu, J., H. Kawai, D. Wiederschain, and Z. M. Yuan. 2001. Mechanism of functional inactivation of a Li-Fraumem syndrome p53 that has a mutation outside of the DNA-binding domain. Cancer Res. 61:1741-1746.
16. Hachiya, M., A. Chumakov, C. W. Miller, M. Akashi, J. Said, and H. P. Koeffler. 1994. Mutant p53 proteins behave in a dominant, negative fashion in vivo. Anticancer Res. 14:1853-1859.
17. Harris, C. C. 1993. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 262:1980-1981.
18. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49-53.
19. Hsu, I. C., R. A. Metcalf, T. Sun, J. A. Welsh, N. J. Wang, and C. C. Harris. 1991. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350:427-428.
20. Irwin, M. S., and W. G. Kaelin. 2001. p53 family update: p73 and p63 develop their own identities. Cell Growth Differ. 12:337-349.
21. Ishimoto, O., C. Kawahara, K. Enjo, M. Obinata, T. Nukiwa, and S. Ikawa. 2002. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 62:636-641.
22. Jeffrey, P. D., S. Gorina, and N. P. Pavletich. 1995. Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science 267:1498-1502.
23. Kern, S. E., J. A. Pietenpol, S. Thiagatingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830.
24. Leung, K. M., L. S. Po, F. C. Tsang, W. Y. Siu, A. Lau, H. T. Ho, and R. Y. C. Poon. 2002. The candidate tumor suppressor ING1b can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res. 62:4890-4893.
25. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
26. McLure, K. G., and P. W. Lee. 1998. How p53 binds DNA as a tetramer. EMBO J. 17:3342-3350.
27. Milner, J., and E. A. Medcalf. 1991. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765-774.
28. Nakagawa, T., M. Takahashi, T. Ozaki, K. Watanabe Ki, S. Todo, H. Mizuguchi, T. Hayakawa, and A. Nakagawara. 2002. Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. Mol. Cell. Biol. 22:2575-2585.
29. Nicholls, C. D., K. G. McLure, M. A. Shields, and P. W. Lee. 2002. Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J. Biol. Chem. 277:12937-12945.
30. Ongkeko, W. M., X. Q. Wang, W. Y. Siu, A. W. S. Lau, K. Yamashita, A. L. Harris, L. S. Cox, and R. Y. C. Poon. 1999. MDM2 and MDMX bind and stabilize the tumor suppressor p53-related protein p73. Curr. Biol. 9:829-832.
31. Poon, R. Y. C., H. Toyoshima, and T. Hunter. 1995. Redistribution of the CDK inhibitor p27 between different cyclin. CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. Mol. Biol. Cell 6:1197-1213.
32. Pozniak, C. D., S. Radinovic, A. Yang, F. McKeon, D. R. Kaplan, and F. D. Miller. 2000. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289:304-306.
33. Rovinski, B., and S. Benchimol. 1988. Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene 2:445-452.
34. Sayan, A. E., B. S. Sayan, N. Findikli, and M. Ozturk. 2001. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells. Oncogene 20:5111-5117.
35. Srivastava, S., S. Wang, Y. A. Tong, K. Pirollo, and E. H. Chang. 1993. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53. Oncogene 8:2449-2456.
36. Stiewe, T., C. C. Theseling, and B. M. Putzer. 2002. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J. Biol. Chem. 277:14177-14185.
37. Varley, J. M. 2003. Germline TP53 mutations and Li-Fraumeni syndrome. Hum. Mutat. 21:313-320.
38. Vikhanskaya, F., M. D'Incalci, and M. Broggini. 2000. p73 competes with p53 and attenuates its response in a human ovarian cancer cell line. Nucleic Acids Res. 28:513-519.
39. Vogelstein, B., and K. W. Kinzler. 1992. p53 function and dysfunction. Cell 70:523-526.
40. Vogelstein, B., and K. W. Kinzler. 1994. Tumour-suppressor genes. X-rays strike p53 again. Nature 370:174-175.
41. Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408:307-310.
42. Wang, X., T. Arooz, W. Y. Siu, C. H. Chiu, A. Lau, K. Yamashita, and R. Y. C. Poon. 2001. MDM2 and MDMX can interact differently with ARF and members of the p53 family. FEBS Lett. 490:202-208.
43. Wang, X. Q., W. M. Ongkeko, A. W. Lau, K. M. Leung, and R. Y. C. Poon. 2001. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res. 61:1598-1603.
44. Wang, Y., J. F. Schwedes, D. Parks, K. Mann, and P. Tegtmeyer. 1995. Interaction of p53 with its consensus DNA-binding site. Mol. Cell. Biol. 15:2157-2165.
45. Yam, C. H., R. W. Ng, W. Y. Siu, A. W. Lau, and R. Y. C. Poon. 1999. Regulation of cychn A-Cdk2 by SCF component Skp1 and F-box protein Skp2. Mod. Cell. Biol. 19:635-645.
46. Yam, C. H., W. Y. Siu, T. Arooz, C. H. Chiu, A. Lau, X. Q. Wang, and R. Y. C. Poon. 1999. MDM2 and MDMX inhibit the transcriptional activity of ectopically expressed SMAD proteins. Cancer Res. 59:5075-5078.
47. Yam, C. H., W. Y. Siu, A. Lau, and R. Y. C. Poon. 2000. Degradation of cyclin A does not require its phosphorylation by CDC2 and cyclin-dependent kinase 2. J. Biol. Chem. 278:3158-3167.
48. Yang, A., M. Kaghad, D. Caput, and F. McKeon. 2002. On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 18:90-95.
49. Yang, A., M. Kaghad, Y. Wang, E. Gillett, M. D. Fleming, V. Dotsch, N. C. Andrews, D. Caput, and F. McKeon. 1998. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2:305-316.
50. Yang, A., and F. McKeon. 2000. P63 and P73: P53 mimics, menaces and more. Nat. Rev. Mol. Cell Biol. 1:199-207.
51. Yang, A., N. Walker, R. Bronson, M. Kaghad, M. Oosterwegel, J. Bonnin, C. Vagner, H. Bonnet, P. Dikkes, A. Sharpe, F. McKeon, and D. Caput. 2000. p73-deficient mice have neurological, phenomenal and inflammatory defects but lack spontaneous tumours. Nature 404:99-103.
52. Yin, Y., C. W. Stephen, M. G. Luciani, and R. Fahraeus. 2002. p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nat. Cell Biol. 4:462-467.
53. Zacharatos, P. V., V. G. Gorgoulis, A. Kotsinas, E. N. Manolis, T. Liloglou, A. N. Rassidakis, P. Kanavaros, J. D. Field, T. Halazonetis, and C. Kittas. 1999. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAF1/Cip1 and Bax genes in the lung cancer environment. WAF1/Cip1 = WAF1/Cip1. Anticancer Res. 19:579-587.
54. Zhu, J., W. Zhou, J. Jiang, and X. Chen. 1998. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J. Biol. Chem. 273:13030-13036.